Mage Biologics Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Financing Rounds
-
1
Mage Biologics General Information
Description
Developer of a monoclonal antibody treatment intended for targeting ulcerative colitis. The company specializes in developing a novel, orally administered monoclonal antibody to clinical proof of concept for the treatment of ulcerative colitis, enabling healthcare providers to better treat patients with ulcerative colitis.
Contact Information
Corporate Office
- Munich
- Germany
Corporate Office
- Munich
- Germany
Mage Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mage Biologics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mage Biologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Mage Biologics FAQs
-
When was Mage Biologics founded?
Mage Biologics was founded in 2023.
-
Where is Mage Biologics headquartered?
Mage Biologics is headquartered in Munich, Germany.
-
What industry is Mage Biologics in?
Mage Biologics’s primary industry is Drug Discovery.
-
Is Mage Biologics a private or public company?
Mage Biologics is a Private company.
-
What is Mage Biologics’s current revenue?
The current revenue for Mage Biologics is .
-
How much funding has Mage Biologics raised over time?
Mage Biologics has raised $27.2M.
-
Who are Mage Biologics’s investors?
Tillots Pharma and TVM Capital Life Science have invested in Mage Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
